Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
3-1-2020

Primary Sclerosing Cholangitis: Epidemiology, Genetics,
Diagnosis, and Current Management.
Eric Gochanour
Liver Care Network and Organ Care Research Swedish Medical Center Seattle WA

Channa Jayasekera
Kris V Kowdley
Liver Care Network and Organ Care Research Swedish Medical Center Seattle WA

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Gastroenterology Commons, and the Hepatology Commons

Recommended Citation
Gochanour, Eric; Jayasekera, Channa; and Kowdley, Kris V, "Primary Sclerosing Cholangitis: Epidemiology,
Genetics, Diagnosis, and Current Management." (2020). Articles, Abstracts, and Reports. 3090.
https://digitalcommons.psjhealth.org/publications/3090

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St.
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org.

Review

Primary Sclerosing Cholangitis:
Epidemiology, Genetics, Diagnosis,
and Current Management
Eric Gochanour, M.D.,* Channa Jayasekera, M.D.,†
and Kris Kowdley, M.D.*

Primary sclerosing cholangitis (PSC) is a rare, idiopathic, and progressive biliary tract disease that can
lead to liver fibrosis and cirrhosis. PSC is characterized
by inflammation and destruction of intrahepatic and extrahepatic bile ducts, leading to progressive hepatic fibrosis.1 The etiology of PSC is unknown, although several
genes are associated with its development and clinical
course.2,3 There is a strong association between inflammatory bowel disease (IBD) of the colon and PSC.1,2 An
overlap syndrome of autoimmune hepatitis and PSC is
an additional, well-established presentation, particularly
in younger patients. The diagnosis of PSC relies heavily
on characteristic cholangiographic features in the setting
of cholestatic liver enzyme abnormalities.2 Patients with
PSC are at increased risk for cholangiocarcinoma and
gallbladder cancer, as well as colon cancer in those with
concurrent IBD.4 Screening for malignancies involving the
gallbladder, bile ducts, and colon is therefore a critical

component of PSC management. Liver transplantation is
by far the most effective treatment, although a posttransplant recurrence rate of approximately 20% is reported.
This review aims to highlight the most salient aspects of
identifying and managing this unique cholestatic liver
disease.

EPIDEMIOLOGY
PSC is a rare disorder with regional variation in prevalence.3 The prevalence in the United States is estimated
to be 1 to 16 per 100,000.1 An estimated 80% of patients diagnosed with PSC have concurrent IBD.2 There
is a 2:1 male predominance when PSC is associated with
IBD and a slight female predominance in the absence of
IBD (Table 1).1 Average age at diagnosis is typically 30 to
40 years old.1 In patients with IBD, the prevalence rate of
PSC is estimated to be approximately 5%.3

Abbreviations: ERC, endoscopic retrograde cholangiography; IBD, inflammatory bowel disease; MRC, magnetic resonance
cholangiography; PSC, primary sclerosing cholangitis.
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TABLE 1. PSC EPIDEMIOLOGY

THE ROLE OF IMAGING IN PSC

Characteristics

Given the limitations of liver histology and absence of
sensitive serological assays, it is essential to perform cholangiography when PSC is suspected. Magnetic resonance
cholangiography (MRC) is now recommended by all major
professional societies as the initial diagnostic modality of
choice2,3,5,6 (Table 2).

Sex: Men (2:1)
Age at Diagnosis: Fourth to fifth decade of life
IBD in PSC: 80%
PSC in IBD: 5%

GENETICS
The pathogenesis of PSC remains unclear, although
multiple genes have been implicated in its development.3
An immunologically mediated process is supported by
known associations with human leukocyte antigens.3
Another theory involves bacterial translocation to the
biliary tree based on an animal model of bacterial overgrowth and link with ulcerative colitis.3,4 Certain gene
mutations including cystic fibrosis transmembrane receptor (CFTR) mutations have also been associated with the
development of PSC.3,4

DIAGNOSIS
Patients with PSC are often asymptomatic early in the
disease course; usually they are identified through a persistent cholestatic pattern of elevated liver enzymes.2
Fatigue and pruritus are common symptoms, but many
patients are asymptomatic. Biliary tract obstruction may
lead to acute pruritus and/or cholangitis, presenting with
jaundice, fever, and abdominal pain. Patients with PSCIBD may present with abnormal bowel habits, abdominal
pain, and intestinal bleeding, with concurrent liver enzyme
abnormalities.

Even though MRC is highly sensitive and specific (0.86
and 0.94, respectively) in detecting the multifocal biliary
stricturing and peripheral pruning phenotype of largeduct PSC, indeterminate cases warrant consideration of
endoscopic retrograde cholangiography (ERC), which remains the reference standard for cholangiography (Fig. 1).
Isolated involvement of peripheral ductules (small-duct
TABLE 2. DIAGNOSING PSC
MRCP

ERCP

Noninvasive

Greater sensitivity

Less expensive

Allows for therapeutic
intervention

Liver Biopsy
Used to rule out
overlapping conditions

No radiation exposure
Eliminates risk for
pancreatitis

The differential diagnosis of PSC includes secondary
sclerosing cholangitis, immunoglobulin G4–associated
cholangitis, autoimmune hepatitis, primary biliary cholangitis, ischemic cholangiopathy, papillary tumors, cholangiocarcinoma, cholangiolithiasis, and HIV cholangiopathy.3
These causative factors should be evaluated during the
diagnostic workup.
Liver biopsy is usually unnecessary in diagnosing PSC,
but it is helpful to evaluate PSC-autoimmune hepatitis
overlap syndrome and small-duct PSC.3 Characteristic features of PSC on histology include concentric periductal
“onion skinning” fibrosis, although this distinctive feature
is insensitive.3 Similarly, there are no known sensitive serological assays for PSC.

FIG 1 Endoscopic retrograde cholangiography demonstrating
focal strictures and dilations creating characteristic “beading”
appearance of intrahepatic bile ducts.
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TABLE 3. COMPLICATIONS OF PSC
Cholangitis
Gastrointestinal malignancies
Fat-soluble vitamin deficiencies
Bone diseases
Cirrhosis and portal hypertension

PSC) is seen in less than 10% of cases, necessitating liver
biopsy because both MRC or ERC are insensitive for smallduct changes.7 Although useful for diagnosis, neither
baseline nor serial cholangiographic features predict disease progression or prognosis in PSC.
The increased risk for clinically significant biliary
obstruction, cholelithiasis, hepatolithiasis, cholangiocellular dysplasia and cholangiocarcinoma, hepatocellular carcinoma, polyps and cancer of the gallbladder, and colon
cancer drives the vital role of regular imaging in the longterm management of PSC (Table 3).

Screening for Malignancy and Premalignant States
Despite the modest positive predictive values, most professional societies and expert opinion support screening for
cholangiocarcinoma with ultrasonography, MRC, and ERC,
with or without serum CA 19-9 every 6 to 12 months.2,3,5
Annual ultrasonography is the recommended modality for gallbladder polyp and cancer screening. As with
patients without PSC, the presence of advanced (stage 3)
liver fibrosis or cirrhosis warrants hepatocellular carcinoma
screening every 6 months, with ultrasonography, computed tomography, or magnetic resonance imaging, with
or without serum alpha-fetoprotein. Elastography modalities (e.g., FibroScan, magnetic resonance elastography) for
fibrosis staging in PSC require further validation. Even in
asymptomatic individuals, colonoscopy to screen for IBD is
recommended in all patients at PSC diagnosis. Presence of
concurrent PSC and IBD warrants colon cancer screening
with colonoscopy every 1 to 2 years.2,5 European guidelines additionally recommend colonoscopy with random
colonic biopsies for IBD screening every 5 years in patients
with PSC who do not have concurrent IBD.5

Imaging Directed by Clinical Features
Differentiating malignant and benign dominant biliary
strictures is difficult. Nevertheless, the development of
dominant biliary strictures should prompt an exhaustive
evaluation for cholangiocarcinoma. Despite very high specificity, sensitivity for cholangiocarcinoma of brush cytology

obtained on ERC is only 43%.8 The addition of fluorescent
in situ hybridization increases sensitivity to 68%, although
specificity decreases to 70%.8,9 Pooled data from small studies of endoscopic retrograde cholangioscopy with targeted
biopsy demonstrate a 65% sensitivity and 97% specificity.10

CURRENT MANAGEMENT
There are no approved pharmacological therapies for
PSC. Ursodeoxycholic acid is the best studied, although
the role of this therapy in PSC remains unclear.3 Highdose ursodeoxycholic acid (>28 mg/kg/day) is associated
with increased adverse clinical outcomes and should be
avoided.11 Despite enthusiasm about its use as a possible
therapy for PSC, recent studies with oral vancomycin have
not shown significant benefit, and randomized clinical trials are needed.3 Patients with decompensated cirrhosis
caused by PSC or with refractory cholangitis may be best
treated with liver transplantation. Liver transplantation has
shown success for selected patients with hilar cholangiocarcinoma caused by PSC.12 Recurrent PSC is estimated to
occur in approximately 20% of patients.3
As with other cholestatic liver diseases, osteopenia may
be a complication of PSC, and bone density screening at
diagnosis and at 2- to 4-year intervals is suggested.3 Fatsoluble vitamin deficiencies may occur.3

PROGNOSIS
The disease course of PSC is highly variable. Serum
alkaline phosphatase levels <1.5× upper limit of normal
have been associated with improved survival in patients
with PSC,13 whereas patients with alkaline phosphatase
levels ≥2.4× upper limit of normal are more likely to die or
require liver transplantation.14

CONCLUSION
PSC is a rare idiopathic cholestatic liver disease with no
approved treatment, although a number of agents are currently showing promise in clinical trials. The disease course is
variable, and management is focused on mitigating several
life-threatening complications, including hepatic and extrahepatic malignancies, with emphasis on early consideration
of liver transplantation in appropriately selected patients;
liver transplantation is an effective treatment for end-stage
liver disease. Disease recurrence has been reported but does
not reduce favorable long-term outcomes.
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